{"organizations": [], "uuid": "98dca8f4111a454435e15e868405c9c737d418c0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180510.html", "section_title": "Archive News &amp; Video for Thursday, 10 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-strongbridge-biopharma-reports-q1/brief-strongbridge-biopharma-reports-q1-non-gaap-loss-per-share-of-0-33-idUSASC0A1E8", "country": "US", "domain_rank": 408, "title": "BRIEF-Strongbridge Biopharma Reports Q1 Non-GAAP Loss Per Share Of $0.33", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.019, "site_type": "news", "published": "2018-05-10T19:38:00.000+03:00", "replies_count": 0, "uuid": "98dca8f4111a454435e15e868405c9c737d418c0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-strongbridge-biopharma-reports-q1/brief-strongbridge-biopharma-reports-q1-non-gaap-loss-per-share-of-0-33-idUSASC0A1E8", "ord_in_thread": 0, "title": "BRIEF-Strongbridge Biopharma Reports Q1 Non-GAAP Loss Per Share Of $0.33", "locations": [], "entities": {"persons": [{"name": "strongbridge biopharma", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "keveyis", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10 (Reuters) - Strongbridge Biopharma plc:\n* REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* Q1 NON-GAAP LOSS PER SHARE $0.33\n* Q1 GAAP LOSS PER SHARE $0.66 * Q1 EARNINGS PER SHARE VIEW $-0.40 â€” THOMSON REUTERS I/B/E/S\n* INCREASED FULL-YEAR 2018 REVENUE GUIDANCE FOR KEVEYIS TO $18 TO $20 MILLION\n* STRONGBRIDGE HAD $92.4 MILLION OF CASH AND CASH EQUIVALENTS AND $86.5 MILLION IN OUTSTANDING DEBT AS OF MARCH 31, 2018\n* MACRILEN (MACIMORELIN) PRODUCT LAUNCH ON TRACK FOR JULY 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-10T19:38:00.000+03:00", "crawled": "2018-05-11T12:36:19.023+03:00", "highlightTitle": ""}